Interesting when you look at an addendum to a previous post that says
As for the US market. I honestly don’t think that this product would be super-competitive in the US market anymore*.
*12/10/2015 : as a device, as opposed to a pharmaceutical.
The new executive director is looking at Fundraising = bringing in outside money ? capital raising for the trial and development, plus if I rad that correctly now talking about marketing it as a pharmaceutical. A more difficult FDA journey but I guess if you are going to do the trial, you do it right in the planning
TIS Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held
